Corvidia Therapeutics, a precision cardiovascular company, today announced the appointment of Sylvie Grégoire as Chair of its Board of Directors, effective immediately. Dr. Grégoire brings over 25 years of experience in leadership roles at both public and private companies.

"We are thrilled that Dr. Grégoire has agreed to chair our Board," said Michael Davidson, MD, Chief Executive Officer of Corvidia Therapeutics. "She possesses exceptional leadership skills and a broad base of experience, including commercial, regulatory, clinical development and manufacturing oversight, all of which are critical to a small, start-up company focused on initiating our first pivotal trial involving precision medicine later this year."

"I am delighted to chair Corvidia's Board of Directors. The company has strong potential for success, with a solid management team backed by top-tier venture funds and a technology platform with the potential to address serious unmet medical needs with novel compounds," noted Dr. Grégoire. "I look forward to working together with the Board and Corvidia's management team in order to bring their compounds forward into development."

In addition to her current Board positions at Novo Nordisk and Galenica, from 2007 to 2013, Dr. Grégoire served as President of the Human Genetic Therapies division of Shire plc, a public biopharmaceutical company. From 2005 to 2008, Dr. Grégoire was a director of IDM Pharma, Inc., a public biotechnology company that now operates as a subsidiary of Takeda Pharmaceuticals, and served as its Executive Chair from August 2006 toOctober 2007. Earlier in her career, Dr. Grégoire was a member of the executive management team of Biogen, Inc., leading Regulatory Affairs and Technical Operations. Dr. Grégoire holds a Bachelor of Pharmacy degree from Laval University in Quebec, and a Pharmacy Doctoral degree from the State University of New York at Buffalo.

Corvidia Therapeutics

Based in Boston, MA, Corvidia is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company's founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia's pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. For more information, please visit: www.corvidiatx.com